Literature DB >> 12473765

Evaluation of clinical diagnostic criteria for neurofibromatosis 2.

M E Baser1, J M Friedman, A J Wallace, R T Ramsden, H Joe, D G R Evans.   

Abstract

BACKGROUND: Four sets of clinical diagnostic criteria for neurofibromatosis 2 (NF2) have been developed by groups of expert clinicians, but sensitivity has never been formally assessed. The sets of criteria differ for people without bilateral vestibular schwannomas, which are pathognomonic for NF2.
OBJECTIVE: To empirically evaluate the four existing sets of clinical diagnostic criteria for NF2.
METHODS: The study was based on 163 of 403 people in the United Kingdom NF2 registry (41%) who presented without bilateral vestibular schwannomas. The authors applied the sets of criteria to each person at initial assessment and at the most recent clinical evaluation (mean +/- SE length of follow-up, 13 +/- 1 years).
RESULTS: In people with "definite NF2" and a negative family history of NF2, the 1987 US NIH and 1991 NIH criteria each identify 78% of people at the most recent clinical evaluation but 0% at initial assessment. The National Neurofibromatosis Foundation (NNFF) criteria and the Manchester criteria each identify higher proportions at both time points (NNFF criteria, 91% and 10%; Manchester criteria, 93% and 14%), but the proportions at initial assessment are still low.
CONCLUSIONS: None of the existing sets of criteria are adequate at initial assessment for diagnosing people who present without bilateral vestibular schwannomas as having NF2, particularly people with a negative family history of NF2. The authors recommend that a single, revised set of diagnostic criteria be devised to replace all of the existing sets of criteria.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12473765     DOI: 10.1212/01.wnl.0000035638.74084.f4

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

Review 1.  Neurocutaneous Disorders for the Practicing Neurologist: a Focused Review.

Authors:  Anna Carolina Paiva Costa T Figueiredo; Nikolas Mata-Machado; Matthew McCoyd; José Biller
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

2.  Intraosseous schwannoma in schwannomatosis.

Authors:  T G Kashima; M R J P Gibbons; D Whitwell; C L M H Gibbons; K M Bradley; S J Ostlere; N A Athanasou
Journal:  Skeletal Radiol       Date:  2013-08-31       Impact factor: 2.199

3.  Choroid plexus papilloma metastases to both cerebellopontine angles mimicking neurofibromatosis type 2.

Authors:  Abdulelah A Al-Abdullah; Khaled K Abu-Amero; Ali Hellani; Hisham Alkhalidi; Thomas M Bosley
Journal:  J Neurol       Date:  2010-09-26       Impact factor: 4.849

Review 4.  Neurofibromatosis type 2.

Authors:  Ashok R Asthagiri; Dilys M Parry; John A Butman; H Jeffrey Kim; Ekaterini T Tsilou; Zhengping Zhuang; Russell R Lonser
Journal:  Lancet       Date:  2009-05-22       Impact factor: 79.321

5.  Spinal meningioma in childhood: clinical features and treatment.

Authors:  Xiao-Qiang Wang; Xian-Wei Zeng; Bi-Yun Zhang; Ya-Fang Dou; Jin-Song Wu; Cheng-Chuan Jiang; Ping Zhong; Hong Chen
Journal:  Childs Nerv Syst       Date:  2011-09-25       Impact factor: 1.475

Review 6.  The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2.

Authors:  M E Baser; L Kuramoto; R Woods; H Joe; J M Friedman; A J Wallace; R T Ramsden; S Olschwang; E Bijlsma; M Kalamarides; L Papi; R Kato; J Carroll; C Lázaro; F Joncourt; D M Parry; G A Rouleau; D G R Evans
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

7.  Development of NF2 gene specific, strictly sequence defined diagnostic microarray for deletion detection.

Authors:  Kiran K Mantripragada; Patrick G Buckley; Caroline Jarbo; Uwe Menzel; Jan P Dumanski
Journal:  J Mol Med (Berl)       Date:  2003-06-27       Impact factor: 4.599

8.  Identification of mutations in the NF2 gene in Polish patients with neurofibromatosis type 2.

Authors:  Mikołaj Łaniewski-Wołłk; Monika Gos; Andrzej Koziarski; Agnieszka Szpecht-Potocka
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

9.  Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.

Authors:  Jaishri O Blakeley; Xiaobu Ye; Dan G Duda; Chris F Halpin; Amanda L Bergner; Alona Muzikansky; Vanessa L Merker; Elizabeth R Gerstner; Laura M Fayad; Shivani Ahlawat; Michael A Jacobs; Rakesh K Jain; Christopher Zalewski; Eva Dombi; Brigitte C Widemann; Scott R Plotkin
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

Review 10.  Neurofibromatosis type 2 (NF2): a clinical and molecular review.

Authors:  D Gareth R Evans
Journal:  Orphanet J Rare Dis       Date:  2009-06-19       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.